SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Involving Possible Securities Fraud Violat...
October 28 2016 - 11:45AM
Business Wire
Levi & Korsinsky, LLP announces that it has commenced an
investigation of Proteostasis Therapeutics, Inc. (“Proteostasis
Therapeutics” or the “Company”) (NASDAQ:PTI) concerning possible
violations of federal securities laws by the Company and/or certain
of its officers and directors.
On October 27, 2016, Proteostasis announced in a conference call
that the results from its Phase 1 study of PTI-428 will be delayed
to the first quarter of 2017. According to Proteostasis, the delay
is due to the murder of a participant in the healthy volunteers
trial and the resulting media attention, which slowed recruitment.
The Company also cited Hurricane Matthew as an additional cause for
the delay, as three trial sites were in the path of the storm.
Following this news, shares of Proteostasis fell from a close of
$12.85 per share on October 26, 2016, to a most recent close of
$7.77 per share on October 28, 2016. To obtain additional
information about the investigation, go to:
http://zlk.9nl.com/proteostasis-therapeutics-pti
or contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits.
Attorney advertising. Prior results do not guarantee similar
outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161028005653/en/
Levi & Korsinsky, LLPJoseph E. Levi, Esq., 212-363-7500Toll
Free: 877-363-5972Fax: 212-363-7171www.zlk.com
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024